Integrum
Integrum publishes preliminary financial key figures for the second quarter 2025/26
Preliminary financial results, Q2 2025/26 (Aug-Oct 2025)
- Net sales: SEK 22.3 million (21.8), an increase of 2.6%.
- Operating result (EBIT): SEK -11.1 million (-11.3).
- Result after tax: SEK -7.4 million (-8.9).
- Earnings per share: SEK -0.35 (-0.46).
- Cash flow: SEK -19.4 million (-12.0).
- Cash and cash equivalents as of 31 October 2025: SEK 7.8 million (34.1).
- Equity ratio: 87.7% (89.8).
- S1 procedures: 43 (40).
Preliminary financial results, May-Oct 2025
- Net sales: SEK 46.1 million (40.2), an increase of 14.7%.
- Operating result (EBIT): SEK -23.5 million (-23.3).
- Result after tax: SEK -17.4 million (-18.4).
- Earnings per share: SEK -0.82 (-0.95).
- Cash flow: SEK -31.8 million (17.2).
The U.S. market continued to develop during the quarter, with sales of SEK 17.9 million (16.6), corresponding to a growth of 7.8 percent (currency-adjusted 18.4%). Sales in EMEA/APAC amounted to SEK 4.5 million (5.2). Cash flow was negatively affected by costs related to the terminated acquisition process with OsteoCentric Technologies.
The company continues to implement the strategic shift announced in February, with a focus on increased commercialization, cost efficiency, and expanded collaborations with leading orthopedic centers in the United States.
"Through the ongoing rights issue, we are strengthening Integrum's financial position and creating room for continued growth," says Martin Hillsten, CEO of Integrum.
The full interim report for the period May-October 2025/26 will be published on 21 November 2025.
This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-11-2025 17:56 CET.
| Datum | 2025-11-13, kl 17:56 |
| Källa | Cision |